Örebro Musculoskeletal Pain Screening Questionnaire | Short Form

The Orebro Musculoskeletal Pain Questionnaire (OMPQ), formerly known as the Acute Low Back Pain Screening Questionnaire (ALBPSQ), predicts long-term disability and work absenteeism in working people suffering from acute and chronic musculoskeletal pain as a result of soft tissue injury.

Validity and Reliability

Cronbach’s alpha and ICC values for the ÖMPSQ-SF total score were 0.71 and 0.77, showing acceptable internal consistency and reliability. The concurrent validity results revealed moderate-to-strong correlations (r = 0.38-0.65) between the ÖMPSQ-SF and other reference questionnaires. The pain intensity, function, distress, fear-avoidance beliefs, and expectations domains of the ÖMPSQ-SF had the highest correlations with their equivalent standard questionnaires (Yoshimoto et al. 2022). Similar results have been reported in other studies from different populations (Özdinç et al. 2022, Ruokolainen et al. 2016)

Scoring and Interpretation

For the full version of the Örebro, the total score will range between 1 and 210, with a score >105 indicating higher estimated risk for future work disability.

These items are assessed on a scale of 0 to 10, with 0 indicating no impairment and 10 indicating severe impairment. Three items, however, must be inverted in order for all of the questions to be orientated in the same direction.

Full Version (go to short version)

For the full version, the scoring instructions are as follows:

• For question 5, count the number of pain sites and multiply by two – this is the score (maximum score allowable is 10).
• For questions 6 and 7 the score is the number bracketed after the ticked box.
• For questions 8, 9, 10, 11, 13, 14, 15, 18, 19 and 20 the score is the number that has been ticked or circled.
• For questions 12, 16, 17, 21, 22, 23, 24 and 25 the score is 10 minus the number that has been circled.
• Write the score in the shaded area beside each item.

A cut-off score of 105 has been discovered to identify individuals who will recover (95% accuracy), those who won’t take any more sick days in the next six months (81% accuracy), and those who will take long-term sick leave (67% accuracy) (Linton et al. 2003).

Örebro PDF Download

DOWNLOAD

Örebro Online Calculator

References

Linton, S. J., Nicholas, M., & MacDonald, S. (2011). Development of a short form of the Örebro Musculoskeletal Pain Screening Questionnaire. Spine, 36(22), 1891–1895. 

Linton SJ, Boersma K. Early identification of patients at risk of developing a persistent back problem: the predictive validity of the Orebro Musculoskeletal Pain Questionnaire. Clin J Pain. 2003;19(2):80-86. 

Gabel, C. P., Melloh, M., Burkett, B., Osborne, J., & Yelland, M. (2012). The Örebro Musculoskeletal Screening Questionnaire: validation of a modified primary care musculoskeletal screening tool in an acute work injured population. Manual therapy, 17(6), 554–565. 

Yoshimoto, T., Yamada, K., Fujii, T., Kawamata, K., Kasahara, S., Oka, H., & Matsudaira, K. (2022). Validity and Reliability of the Japanese Version of the Örebro Musculoskeletal Pain Screening Questionnaire-Short Form for Chronic Low Back Pain. Pain physician, 25(4), E681–E688.

Özdinç, S., Pekçetin, S., Can, H., Ata, H., Süslü, B., & Birtane, M. (2022). Validity and reliability of the Turkish Örebro musculoskeletal pain screening questionnaire-short form. Work (Reading, Mass.), 72(1), 333–341. 

Ruokolainen, O., Haapea, M., Linton, S., Korniloff, K., Häkkinen, A., Paananen, M., & Karppinen, J. (2016). Construct validity and reliability of Finnish version of Örebro Musculoskeletal Pain Screening Questionnaire. Scandinavian journal of pain, 13, 148–153.

Copyright Notice

When available, sources are cited, and the tool’s developer retains ownership of the intellectual property. We consider that the modification and creation of these tools into dynamic, interactive, online scoring calculators is fair usage. Please email us if you believe we have violated your copyright so we can take down the offending material.